Aerie pharmaceuticals to announce third quarter 2017 financial results and host conference call on wednesday, november 8, 2017

Irvine, calif.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri) (aerie or the company), announced today that its third quarter 2017 financial results will be released after the market closes on wednesday, november 8, 2017. following the release, the company will host a live conference call and webcast at 5:00 p.m. eastern time to discuss the company’s financial results and provide a general business update. the live webcast and a replay may be accessed by visiting the company's website at http://investors.aeriepharma.com. please connect to the company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. alternatively, please call (888) 734-0328 (u.s.) or (678) 894-3054 (international) to listen to the live conference call. the conference id number for the live call is 5799149. please dial in approximately 10 minutes prior to the call. telephone replay will be available approximately two hours after the call. to access the replay, please call (855) 859-2056 (u.s.) or (404) 537-3406 (international). the conference id number for the replay is 5799149. the telephone replay will be available until november 15, 2017. about aerie pharmaceuticals, inc. aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. aerie's two current product candidates are once-daily intraocular pressure lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. the nda (new drug application) for rhopressa™ (netarsudil ophthalmic solution) 0.02% was submitted to the u.s. food and drug administration (fda) in february 2017, and, in may 2017, the fda set the pdufa (prescription drug user fee act) goal date for the completion of the fda’s review of the rhopressa™ nda for february 28, 2018. aerie’s second product candidate, roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of rhopressa™ and widely prescribed pga latanoprost, achieved its primary efficacy endpoint in two phase 3 registration trials, named mercury 1 and mercury 2, and also achieved successful 12-month safety and efficacy results in mercury 1. the roclatan™ nda submission is expected to take place in the first half of 2018. aerie is also focused on global expansion and the development of additional product candidates and technologies in ophthalmology.
AERI Ratings Summary
AERI Quant Ranking